Victoza is widely known as a diabetes medication, but many patients also experience weight loss while using it. Here’s how liraglutide changes appetite, digestion, and metabolic health — plus the risks physicians monitor closely.
Patients using older GLP-1 medications like Byetta are increasingly transitioning to newer therapies such as Wegovy and Zepbound. Here’s how the switching process works, why dose escalation matters, and what clinicians consider when choosing between semaglutide and tirzepatide.
Semaglutide, tirzepatide, and retatrutide represent three generations of obesity medications. Here’s how GLP-1, dual-agonist, and triple-agonist therapies compare for weight loss, metabolism, and future obesity treatment.
Retatrutide is an investigational triple-agonist weight loss injection targeting GLP-1, GIP, and glucagon receptors simultaneously. Early trials suggest it may outperform current obesity medications, including Wegovy and Mounjaro.
Retatrutide may become the next major breakthrough in obesity medicine. Here’s how the investigational triple-agonist compares with Wegovy, Mounjaro, and other GLP-1 medications for weight loss and metabolic health.
Saxenda introduced GLP-1 weight-loss therapy to mainstream obesity medicine, but Wegovy dramatically changed expectations with stronger appetite suppression, weekly dosing, and substantially greater weight-loss results. Here’s why semaglutide overtook liraglutide in modern obesity treatment.
Saxenda and Wegovy both belong to the GLP-1 drug class, but their differences in dosing, effectiveness, and appetite control may significantly influence long-term weight-loss habits. Here’s how semaglutide and liraglutide compare in real-world obesity management.
As tirzepatide and semaglutide drive larger weight-loss results, questions about muscle preservation and body composition are becoming increasingly important in obesity medicine.
A major clinical trial found that tirzepatide produced greater average weight loss than semaglutide over 72 weeks. Here’s what researchers believe explains the difference between these two leading obesity medications.
New clinical trial data show that Zepbound users lost significantly more weight than Wegovy users over 72 weeks. Here’s how tirzepatide and semaglutide compare in effectiveness, side effects, cardiovascular benefits, and obesity treatment outcomes.